AR097744A1 - Proceso para producir derivado de diazabiciclooctano y su intermediario - Google Patents

Proceso para producir derivado de diazabiciclooctano y su intermediario

Info

Publication number
AR097744A1
AR097744A1 ARP140103525A ARP140103525A AR097744A1 AR 097744 A1 AR097744 A1 AR 097744A1 AR P140103525 A ARP140103525 A AR P140103525A AR P140103525 A ARP140103525 A AR P140103525A AR 097744 A1 AR097744 A1 AR 097744A1
Authority
AR
Argentina
Prior art keywords
compound represented
formula
dione
alkyl
obn
Prior art date
Application number
ARP140103525A
Other languages
English (en)
Inventor
Abe Takao
Sakamaki Yoshiaki
Furuuchi Takeshi
Mitsuhashi Nakako
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR097744A1 publication Critical patent/AR097744A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

La presente proporciona un proceso para producir un derivado de diazabiciclooctano. Reivindicación 1: Un proceso para producir un compuesto representado por la fórmula (4), caracterizado porque comprende: hacer reaccionar un compuesto representado por la fórmula (1) con R¹OH seleccionado de 1-hidroxipirrolidin-2,5-diona, 2-hidroxi-3a,4,7,7a-tetrahidro-1H-isoindol-1,3(2H)-diona, 2-hidroxihexahidro-1H-isoindol-1,3(2H)-diona y 4-hidroxi-4-azatriciclo[5,2,1,02,6]dec-8-en-3,5-diona permitiendo luego que un agente de carbonilación seleccionado de fosgeno, difosgeno y trifosgeno actúe para obtener un compuesto representado por la fórmula (2) eliminando un grupo protector P y tratándolo con una base para obtener un compuesto representado por la fórmula (3) y haciendo reaccionar con el compuesto: R³ONH₂ para producir el compuesto representado por la fórmula general (4) (en las fórmulas antes mencionadas (1), (2), (3) y (4), OBn es benciloxi; P es un grupo protector NH capaz de ser removido con ácido; R¹ es 2,5-dioxopirrolidin-1-ilo, 1,3-dioxo-3a,4,7,7a-tetrahidro-1H-isoindol-2(3H)-ilo, 1,3-dioxohexahidro-1H-isoindol-2(3H)-ilo o 3,5-dioxo-4-azatriciclo[5,2,1,02,6]dec-8-en-4-ilo; R² es hidrógeno, ClCO⁻ o Cl₃COCO⁻; y R³ es alquilo C₁₋₆ o heterociclilo o forma un anillo heterocíclico de 3 a 7 miembros junto con el -O-NH- adyacente; R³ se puede modificar con 0 a 5 R⁴, y R⁴ se pueden sustituir consecutivamente; R⁴ es alquilo C₁₋₆, alcoxi C₁₋₆, alquil C₁₋₆-sulfonilo, heterociclilo, heterociclilcarbonilo, R⁵(R⁶)N- o un grupo protector; aquí, R⁵ y R⁶ son cada uno, de modo independiente, hidrógeno o alquilo C₁₋₆ o forman juntos un anillo heterocíclico de 3 a 7 miembros; por otra parte, R³, R⁵ y R⁶ se pueden someter a cierre del anillo en una posición arbitraria). Reivindicación 18: Un compuesto representado por la fórmula (5) (caracterizado porque OBn es benciloxi). Reivindicación 21: Un compuesto representado por la fórmula (6) (caracterizado porque Boc es ter-butoxicarbonilo y OBn es benciloxi).
ARP140103525A 2013-09-24 2014-09-24 Proceso para producir derivado de diazabiciclooctano y su intermediario AR097744A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013197110 2013-09-24

Publications (1)

Publication Number Publication Date
AR097744A1 true AR097744A1 (es) 2016-04-13

Family

ID=52743343

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103525A AR097744A1 (es) 2013-09-24 2014-09-24 Proceso para producir derivado de diazabiciclooctano y su intermediario

Country Status (22)

Country Link
US (2) US10000491B2 (es)
EP (1) EP3050883B1 (es)
JP (1) JP6453222B2 (es)
KR (1) KR102239725B1 (es)
CN (2) CN107501264A (es)
AR (1) AR097744A1 (es)
AU (1) AU2014324302B2 (es)
BR (1) BR112016006246B1 (es)
CA (1) CA2924953C (es)
DK (1) DK3050883T3 (es)
ES (1) ES2793201T3 (es)
HK (2) HK1244487A1 (es)
HU (1) HUE049027T2 (es)
IL (1) IL244740B (es)
MX (1) MX367578B (es)
MY (2) MY176278A (es)
NZ (1) NZ718009A (es)
RU (1) RU2719480C2 (es)
SG (1) SG11201602256UA (es)
TW (1) TWI644908B (es)
WO (1) WO2015046207A1 (es)
ZA (1) ZA201602053B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
NZ718009A (en) 2013-09-24 2018-03-23 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
HUE051925T2 (hu) 2013-10-08 2021-04-28 Meiji Seika Pharma Co Ltd Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása
KR102555657B1 (ko) * 2014-12-05 2023-07-18 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 결정 및 안정된 동결 건조 제제의 제조법
CA2944306C (en) 2015-10-30 2023-11-14 The Toronto-Dominion Bank Validating encrypted data from a multi-layer token
US11216808B2 (en) 2015-11-04 2022-01-04 The Toronto-Dominion Bank Token-based system for excising data from databases
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
EP3687992A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
KR20200091394A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 약제학적 형태 및 그의 제조방법
CA3076955A1 (en) 2017-09-27 2019-04-04 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN111373033A (zh) 2017-11-23 2020-07-03 豪夫迈·罗氏有限公司 脯氨酸羟化酶及其相关用途、方法和产品
WO2021038403A1 (en) 2019-08-30 2021-03-04 DePuy Synthes Products, Inc. Electrical device for monitoring, prevention, and treatment of implant infections

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (es) 1970-10-21 1975-12-10
JPS538509A (en) 1976-07-13 1978-01-26 Toshiba Corp Impedance matching system for data transmission circuit
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
CN1048248C (zh) 1994-05-02 2000-01-12 盐野义制药株式会社 吡咯烷基硫基碳代青霉烯衍生物的结晶、含该结晶的冷冻干燥制剂及其制造方法
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2815420B1 (fr) 2000-10-16 2003-05-16 Cit Alcatel Compensation de la dispersion chromatique dans un systeme de transmission a fibre optique, et fibre de compensation
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
SI2231667T1 (sl) 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
ES2622004T3 (es) * 2010-12-22 2017-07-05 Meiji Seika Pharma Co., Ltd. Derivado de diazabiciclooctano ópticamente activo y método para preparar el mismo
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
WO2012172368A1 (en) 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
PL2748165T3 (pl) 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
EP2872510B1 (en) 2011-08-30 2016-11-23 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
NZ718009A (en) 2013-09-24 2018-03-23 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
HUE051925T2 (hu) 2013-10-08 2021-04-28 Meiji Seika Pharma Co Ltd Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása

Also Published As

Publication number Publication date
IL244740B (en) 2018-11-29
KR102239725B1 (ko) 2021-04-12
JP6453222B2 (ja) 2019-01-16
CA2924953C (en) 2021-12-07
BR112016006246A2 (es) 2017-08-22
TWI644908B (zh) 2018-12-21
RU2016115767A (ru) 2017-10-26
CN105555787A (zh) 2016-05-04
MX367578B (es) 2019-08-27
MY176278A (en) 2020-07-27
BR112016006246B1 (pt) 2021-09-08
RU2016115767A3 (es) 2018-06-29
EP3050883A1 (en) 2016-08-03
US10000492B2 (en) 2018-06-19
IL244740A0 (en) 2016-04-21
CN105555787B (zh) 2017-08-08
JPWO2015046207A1 (ja) 2017-03-09
KR20160058851A (ko) 2016-05-25
NZ718009A (en) 2018-03-23
HK1244487A1 (zh) 2018-08-10
ES2793201T3 (es) 2020-11-13
CA2924953A1 (en) 2015-04-02
US20170283415A1 (en) 2017-10-05
AU2014324302A1 (en) 2016-05-12
US10000491B2 (en) 2018-06-19
MX2016003867A (es) 2016-08-04
HUE049027T2 (hu) 2020-08-28
DK3050883T3 (da) 2020-05-25
EP3050883B1 (en) 2020-04-22
WO2015046207A1 (ja) 2015-04-02
US20160264573A1 (en) 2016-09-15
SG11201602256UA (en) 2016-04-28
MY193210A (en) 2022-09-26
EP3050883A4 (en) 2017-05-10
TW201546059A (zh) 2015-12-16
CN107501264A (zh) 2017-12-22
HK1219473A1 (zh) 2017-04-07
RU2719480C2 (ru) 2020-04-17
ZA201602053B (en) 2019-06-26
AU2014324302B2 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
AR097744A1 (es) Proceso para producir derivado de diazabiciclooctano y su intermediario
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
ES2721627T3 (es) Nuevo derivado de amina o sal del mismo como inhibidores de TNF alfa
AR105456A1 (es) Compuestos de piridina con acción fungicida
PE20170144A1 (es) 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR106605A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
AR107293A1 (es) COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
ES2677919T3 (es) Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
AR098912A1 (es) Inhibidores de syk
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
NZ723502A (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
MY178760A (en) Monocyclic pyridine derivative
PE20150021A1 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
AR106258A1 (es) Compuestos de piridina
PE20151748A1 (es) Inhibidores de bace1
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR066605A1 (es) Derivados de heteroarilamida pirimidona

Legal Events

Date Code Title Description
FG Grant, registration